Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (953)

« Back to Publications

Phase I/IIa study to assess the safety, immunogenicity and efficacy of ChAdOx1-MVA vectored vaccines expressing a novel liver-stage malaria dual antigen LS2 by sporozoite challenge in malaria-naïve adults

Silman D. et al, (2026), Wellcome Open Research, 9, 734 - 734

African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African children.

Muriuki JM. et al, (2026), Nature communications

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.

Anywaine Z. et al, (2026), The Lancet. Infectious diseases, 26, 302 - 313

Recent Advances, Bottlenecks, and Future Directions in Plasmodium falciparum Vaccine Development.

Turan G. et al, (2026), Vaccines, 14

An Adenoviral Vectored Vaccine Protects Mice Against Aerosol Challenge with Yersinia pestis.

Dold C. et al, (2026), Molecular therapy : the journal of the American Society of Gene Therapy

Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185

Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].

Mukhopadhyay ES. et al, (2026), Vaccine, 69

B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.

Bundi CK. et al, (2026), Frontiers in immunology, 17

Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM

Mukhopadhyay ES. et al, (2025), Vaccine, 68, 127897 - 127897

Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice

Mukhopadhyay E. et al, (2025), Frontiers in Immunology, 16

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.

McDaniel JR. et al, (2025), The Journal of experimental medicine, 222

Seasonal mass vaccination with R21/Matrix-M for malaria elimination (SERVAL): protocol of the cluster randomised trial.

Dabira ED. et al, (2025), Trials, 26

R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

Kibwana E. et al, (2025), Frontiers in Immunology, 16

Vaccine-induced responses to R21/Matrix-M – an analysis of samples from a phase 1b age de-escalation, dose-escalation trial

Bundi C. et al, (2025), Frontiers in Immunology, 16

Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot

Guyon R. et al, (2025), Science Translational Medicine, 17

Load More

1
2
3
4
5
6
7
...
»